SCHEMBL3572999

SCHEMBL3572999

CC(=O)Nc1cccc(C(=O)c2ccc3c(c2)NC(=O)C3=CNc2ccc(N3CCOCC3)cc2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 2/20 0.48
POLB P06746 2/20 0.44
NTRK3 Q16288 1/20 0.43
MAPT P10636 6/20 0.43
RAB9A P51151 3/20 0.43
ALOX12 P18054 2/20 0.43
ALDH1A1 P00352 4/20 0.42
BRAF P15056 1/20 0.42
PDGFRB P09619 1/20 0.41
MAPK14 Q16539 1/20 0.41
EPHX2 P34913 1/20 0.41
HTT P42858 3/20 0.40
TP53 P04637 1/20 0.40
HPGD P15428 1/20 0.40
LCK P06239 1/20 0.40
RET P07949 1/20 0.40
PDGFRA P16234 1/20 0.40
KDR P35968 1/20 0.40
LRRK2 Q5S007 1/20 0.40
ALK Q9UM73 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3572998 1.00 CSF1R (0.48) CSF1RPOLBNTRK3MAPTRAB9A
SCHEMBL3571618 0.93 JAK3 (0.46) CSF1RPOLBMAPTRAB9AALOX12
SCHEMBL3571619 0.93 JAK3 (0.46) CSF1RPOLBMAPTRAB9AALOX12
SCHEMBL3573781 0.93 CSF1R (0.51) CSF1RPOLBMAPTRAB9AALOX12
SCHEMBL3573782 0.93 CSF1R (0.51) CSF1RPOLBMAPTRAB9AALOX12
SCHEMBL3573380 0.92 CSF1R (0.49) CSF1RNTRK3MAPTRAB9AALDH1A1
SCHEMBL3573384 0.92 CSF1R (0.49) CSF1RNTRK3MAPTRAB9AALDH1A1
SCHEMBL3578295 0.88 CSF1R (0.47) CSF1RMAPTRAB9AALOX12PDGFRB
SCHEMBL3578299 0.87 CSF1R (0.46) CSF1RMAPTRAB9AALOX12PDGFRB
SCHEMBL3581682 0.86 JAK3 (0.48) CSF1RPOLBMAPTRAB9AALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1902025-A1 KINASE INHIBITORS Allergan, Inc. (US) 2008-03-26 EP claimed
US-20070032478-A1 Kinase Inhibitors ALLERGAN, INC. 2007-02-08 US claimed
WO-2007008895-A1 KINASE INHIBITORS ALLERGAN, INC. (US) 2007-01-18 WO claimed
US-7749530-B2 Kinase inhibitors ALLERGAN, INC. (US) 2010-07-06 US disclosed
WO-2010075197-A1 KINASE INHIBITORS ALLERGAN, INC. (US) 2010-07-01 WO disclosed
US-7692005-B2 Kinase inhibitors ALLERGAN, INC. (US) 2010-04-06 US disclosed
US-20090208557-A1 Kinase inhibitors ALLERGAN, INC. 2009-08-20 US disclosed
EP-1902025-A1 KINASE INHIBITORS Allergan, Inc. (US) 2008-03-26 EP disclosed
US-20070032478-A1 Kinase Inhibitors ALLERGAN, INC. 2007-02-08 US disclosed
WO-2007008895-A1 KINASE INHIBITORS ALLERGAN, INC. (US) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090208557-A1 Kinase inhibitors PTK2, MAP3K6, MAP3K20 CSF1R 776/4885POLB 3520/4885NTRK3 444/4885
US-20070032478-A1 Kinase Inhibitors ABL1, LCK, ERBB2 CSF1R 877/4885POLB 1863/4885NTRK3 418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.